What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
关于ligand pharmaceuticals公司的分析师评级有哪些？
Deciphering Analyst Ratings: An...4 analysts have expressed a variety of opinions on Ligand Pharmaceuticals (NASDAQ:LGND) over the past quarter, offering a diverse set of opinions from bullish to bearish.
过去一个季度，有4个分析师对Ligand Pharmaceuticals (纳斯达克:LGND) 表达了不同的看法，其中观点从看好到看淡不一。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析师最近的评级概述，为了全面了解过去30天的情绪变化并与前几个月进行比较，提供了深入的见解。
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $119.5, with a high estimate of $144.00 and a low estimate of $95.00. This current average has decreased by 6.4% from the previous average price target of $127.67.
分析师对未来12个月价格目标的评估提供了额外的信息，展示了平均目标价119.5美元，最高估价144.00美元，最低估价95.00美元。当前平均价格目标较上一个平均价格目标127.67美元下降了6.4%。
Deciphering Analyst Ratings: An...
分析师评...
登录免费看全文
登录/注册
资讯热榜
更新时间